地热能是可再生能源之一,而地源热泵系统是应用地热能的一种重要方式。为提升工作效率,基于Visual Studio 2022开发平台,以C#编程语言下的WPF框架开发了一款地源热泵多能耦合系统方案设计软件,并依托于某项目对该软件在实际工程中的可...地热能是可再生能源之一,而地源热泵系统是应用地热能的一种重要方式。为提升工作效率,基于Visual Studio 2022开发平台,以C#编程语言下的WPF框架开发了一款地源热泵多能耦合系统方案设计软件,并依托于某项目对该软件在实际工程中的可用性、准确性进行了验证。该软件运行结果表明选用2台某地源热泵机组及5台某空气源热泵机组可承担该项目冷热负荷,每年耗能为4347.36MWh,总能耗费用449.53万元,单平米能耗费用33.30元/m^(2),在得到特定比例补贴的情况下投资成本总计3545.92万元,单平米造价262.66元/m^(2),与原设计方案一致。展开更多
Chronic hepatitis C virus(HCV) infection is a public health issue that often progresses to life-threatening complications, including liver cirrhosis, fibrosis, and hepatocellular carcinoma. Impaired immune responses t...Chronic hepatitis C virus(HCV) infection is a public health issue that often progresses to life-threatening complications, including liver cirrhosis, fibrosis, and hepatocellular carcinoma. Impaired immune responses to HCV are key features of chronic HCV infection. Therefore, intervention strategies usually involve enhancing the immune responses against HCV. Cytotoxic CD8+ T lymphocytes(CTLs) play a critical role in the control of HCV infection. However, their cytolytic function can be impaired by the expression of co-inhibitory molecules. Programmed death-1(PD-1) receptor and its ligand PD-L1 function in a T cell co-inhibitory pathway, which either blocks the function of CTLs or the differentiation of CD8+ T cells. During chronic HCV infection, the immune inhibitory receptor PD-1 is upregulated on dysfunctional HCV-specific CD8+ T cells. As such, blockade of the PD-1/PD-L1 pathway in these CD8+ T cells might restore their functional capabilities. Indeed, clinical trials using therapies to block this pathway have shown promise in the fostering of anti-HCV immunity. Understanding how chronic HCV infection induces upregulation of PD-1 on HCV specific T cells and how the PD-1/PD-L1 interaction develops HCV specific T cell dysfunction will accelerate the development of an efficacious prophylactic and therapeutic vaccination against chronic HCV infections, which will significantly improve HCV treatments and patient survival. In this review, we discuss the relationship between PD-1 expression and clinical responses and the potential use of PD-1 blockade for anti-HCV therapy.展开更多
文摘地热能是可再生能源之一,而地源热泵系统是应用地热能的一种重要方式。为提升工作效率,基于Visual Studio 2022开发平台,以C#编程语言下的WPF框架开发了一款地源热泵多能耦合系统方案设计软件,并依托于某项目对该软件在实际工程中的可用性、准确性进行了验证。该软件运行结果表明选用2台某地源热泵机组及5台某空气源热泵机组可承担该项目冷热负荷,每年耗能为4347.36MWh,总能耗费用449.53万元,单平米能耗费用33.30元/m^(2),在得到特定比例补贴的情况下投资成本总计3545.92万元,单平米造价262.66元/m^(2),与原设计方案一致。
基金Supported by Science and Technology Development Fund(STDFgrants No.1469 and No.5245)Tanta University Fund,Egypt to Mohamed L Salem,the Principal investigator of these projects
文摘Chronic hepatitis C virus(HCV) infection is a public health issue that often progresses to life-threatening complications, including liver cirrhosis, fibrosis, and hepatocellular carcinoma. Impaired immune responses to HCV are key features of chronic HCV infection. Therefore, intervention strategies usually involve enhancing the immune responses against HCV. Cytotoxic CD8+ T lymphocytes(CTLs) play a critical role in the control of HCV infection. However, their cytolytic function can be impaired by the expression of co-inhibitory molecules. Programmed death-1(PD-1) receptor and its ligand PD-L1 function in a T cell co-inhibitory pathway, which either blocks the function of CTLs or the differentiation of CD8+ T cells. During chronic HCV infection, the immune inhibitory receptor PD-1 is upregulated on dysfunctional HCV-specific CD8+ T cells. As such, blockade of the PD-1/PD-L1 pathway in these CD8+ T cells might restore their functional capabilities. Indeed, clinical trials using therapies to block this pathway have shown promise in the fostering of anti-HCV immunity. Understanding how chronic HCV infection induces upregulation of PD-1 on HCV specific T cells and how the PD-1/PD-L1 interaction develops HCV specific T cell dysfunction will accelerate the development of an efficacious prophylactic and therapeutic vaccination against chronic HCV infections, which will significantly improve HCV treatments and patient survival. In this review, we discuss the relationship between PD-1 expression and clinical responses and the potential use of PD-1 blockade for anti-HCV therapy.
